Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

• Principais autores: Diansong Zhou (Autor), Terry Podoll (Autor), Yan Xu (Autor), Ganesh Moorthy (Autor), Karthick Vishwanathan (Autor), Joseph Ware (Autor), J. Greg Slatter (Autor), Nidal Al‐Huniti (Autor)
• Formato: Livro
• Publicado em: Wiley, 2019-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to predict potential drug-drug interactions (DDIs). The...